iLite® TNF-alpha Assay Ready Cells

Add to my product list

The iLite® TNF-alpha Assay Ready Cells are intended for use in a screening assay for anti-TNF alpha activity using luciferase generated bioluminescence.

The cells are engineered cells for use in a normalized reporter gene bioassay for screening of anti-TNF alpha activity in samples. The assay is a simple and easy test format which detects anti-TNF alpha activity and, indirectly, the presence of anti-drug antibodies.

References (using this product):

  1. Lallemand C, Kavrochorianou A, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet J-F, Blanchard B, Lebon P, Taylor P, Charles P, Alzabin S, Tovey MG. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF-alpha antagonists. J Immunol Meth. 2011, 373: 229-239.
  2. Pavlov I, Carper J, Lázár-Molnár E, Delgado JC. Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clinica Chimica Acta. 2016, 453:147-153.

Product code
BM3044
Format
Assay Ready Cells
Shelf life
18 months
Calculation
Semi-quantitative
Antibody class detected
Neutralizing Antibodies to anti TNF drugs
Antigen
Anti TNF drugs
Units
Drug assays: ng/mL
NAb assays: antibody titre
Range
anti TNF Drug Assays
IFX Drug 10-40ng/mL
ALD Drug 5-30 ng/mL
ETN Drug 2-10 ng/mL
Neutralizing antibodies to anti TNF drug
20 – 2560 Antibody Titre. Samples can be further diluted to detect higher titre samples, there is no maximum range of detection.
Incubation time
Drug Assays 30 min + 3 hours
NAb Assays 30 min + 30 min +3 hours
Detection system
Luminescence
Availability
Research use only

The iLite® TNF-alpha Assay Ready Cells are intended for use in a screening assay for anti-TNF-alpha activity or testing NAb anti-TNF-alpha activity, using luciferase generated bioluminescence.

TNF-alpha promotes inflammatory responses, which, in turn, contribute to the clinical problems associated with many inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and refractory asthma. These diseases are sometimes treated with monoclonal anti-TNF-alpha antibody constructs, including infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), or golimumab (Simponi). Prolonged therapies with these TNF-alpha inhibitors may lead to development of neutralizing antibodies (NAbs) which may counteract the TNF-alpha antagonist activity of the drugs. The iLite® TNF-alpha reporter cells are engineered cells for use in a normalized reporter gene bioassay for screening of anti-TNF-alpha activity in samples. The assay is a simple and easy test format which detects anti-TNF-alpha activity and, indirectly, the presence of anti-drug antibodies.

iLite® TNF-alpha Assay Ready Cells 1 vial (1.5 mL)